This content is machine translated Tailored surgery for lung cancer Trend toward limited minimally invasive segment resection clearly evident The benefit of lung cancer screening in defined risk groups has been demonstrated in two large studies. In the early stages of the disease, limited resection with lymphadenectomy is the…
View Post 4 min This content is machine translated Cancer prevention, support and aftercare Lifestyle makes the difference Proper diet and exercise reduce cancer risk. If the tumor does strike, they help maintain quality of life. In follow-up, they increase the probability of survival. Update on the data…
View Post 5 min This content is machine translated Small cell and non-small cell lung cancer Rapid progress through immunotherapy and immunochemotherapy Immunotherapy is one of the milestones of cancer therapy. However, the selection of particularly suitable patients remains a major challenge for first-line use.
View Post 6 min This content is machine translated ESMO 2018 in Munich Quantum leap in ovarian cancer? The SOLO-1 trial was one of the “hot” topics at this year’s ESMO. A PFS improvement of 70% with good tolerance and efficacy not only in recurrences suggest a relevant…
View Post 4 min This content is machine translated Cancer in close relatives Perceived vulnerability fuels prevention efforts Is it possible that preventive advice is particularly fruitful for relatives of cancer patients? One study suggests that. The circumstance could be used responsibly for cancer prevention.
View Post 11 min This content is machine translated Ewing's Sarcoma Management of the second most common primary malignant bone tumor Therapy of choice for Ewing’s sarcoma includes neoadjuvant chemotherapy, tumor resection, and postoperative chemotherapy with/without radiotherapy. In this context, interdisciplinary management at an appropriate center is of crucial importance.
View Post 1 min This content is machine translated Special report: maintenance therapy of relapsed ovarian cancer. Niraparib approved with individual starting doses In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula®) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation…
View Post 10 min This content is machine translated Bone Sarcomas Treatment of primary bone tumors of the pelvis Surgical resection represents the mainstay of therapy for pelvic bone sarcomas. Treatment is complex and should be individualized. By sharing data and expert knowledge, the disease can be better understood.…
View Post 9 min This content is machine translated Regional hyperthermia in oncology A practical overview Hyperthermia is a potent radio-sensitizer. The evidence base is good, especially for re-irradiation of tumor recurrences in pre-exposed areas. Thermal radiotherapy as part of primary curative therapy is currently being…
View Post 4 min This content is machine translated 28th German Skin Cancer Congress 2018, Stuttgart Update on immunotherapy of malignant melanoma Combination immunotherapy, adjuvant immune checkpoint blockade, and long-term survival after PD-1 inhibitor therapy were the topics of two satellite symposia at the German Skin Cancer Congress.
View Post 6 min This content is machine translated DGHO in Vienna Prostate and breast cancer: the future belongs to combined therapies Treatment options are often limited in both prostate and breast carcinoma. The search for new effective drugs and combination therapies is therefore the primary goal of current studies.
